CoChat

NILVAD protocol: a European multicentre double-blind placebo-controlled trial of nilvadipine in mild-to-moderate Alzheimer's disease

Open access
Lawlor, Brian, Kennelly, Sean, O'Dwyer, Sarah, Cregg, Fiona, Walsh, Cathal, Coen, Robert, Kenny, Rose Anne, Howard, Robert, Murphy, Caroline, Adams, Jessica, Daly, Leslie, Segurado, Ricardo, Gaynor, Siobhan, Crawford, Fiona, Mullan, Michael, Lucca, Ugo, Banzi, Rita, Pasquier, Florence, Breuilh, Laetitia, Riepe, Matthias, Kalman, Janos, Wallin, Anders, Borjesson, Anne, Molloy, William, Tsolaki, Magda, Olde Rikkert, Marcel · 2014 · BMJ Open
Cited by 45

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

Abstract

Introduction: This study is a European multicentre, randomised, double-blind, placebo-controlled trial investigating the efficacy and safety of nilvadipine as a disease course modifying treatment for mild-to-moderate Alzheimer's disease (AD) in a phase III study that will run for a period of 82 weeks with a treatment period of 78 weeks. Methods and analysis: Adult patients, males and females over 50 years with mild-to-moderate AD as defined by the National Institute of Neurological and Communicative Disorders and Stroke/Alzheimer's disease and Related Disorders Association (NINCDS-ADRDA) criteria, will be included in the study. It aims to recruit a total of 500 patients with AD; 250 in the nilvadipine group and 250 in the placebo group. Participants will be randomised to receive nilvadipine, an 8 mg overencapsulated, sustained release capsule, or a matching overencapsulated placebo (sugar pill) for a period of 78 weeks of treatment. The primary efficacy outcome measure in this study is the change in cognitive function as assessed by the Alzheimer's disease Assessment Scale (ADAS-Cog 12) from baseline to the end of treatment duration (78 weeks). There are two key secondary outcome measures, the Clinical Dementia Rating Scale Sum of Boxes (CDR-sb) and the Disability Assessment for Dementia (DAD). If a statistically significant effect is seen in the primary outcome, CDR-sb will be considered to be a coprimary end point and only the DAD will contribute to the secondary outcome analysis. Ethics and dissemination: The study and all subsequent amendments have received ethical approval within each participating country according to national regulations. Each participant will provide written consent to participate in the study. All participants will remain anonymised throughout and the results of the study will be published in an international peer-reviewed journal. Trial registration number: EUDRACT Reference Number: 2012-002764-27.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1136/bmjopen-2014-006364

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 6 references

Cited by

See all 45

Metadata

Authors
Lawlor, B., Kennelly, S., O'Dwyer, S., Cregg, F., Walsh, C., Coen, R., Kenny, R. A., Howard, R., Murphy, C., Adams, J., Daly, L., Segurado, R., Gaynor, S., Crawford, F., Mullan, M., Lucca, U., Banzi, R., Pasquier, F., Breuilh, L., Riepe, M., Kalman, J., Wallin, A., Borjesson, A., Molloy, W., Tsolaki, M., & Olde Rikkert, M.
Venue
BMJ Open
Publisher
BMJ
Published
2014-10
Volume
4
Issue
10
Pages
e006364
ISSN
2044-6055 (ISSN-L)
OpenAlex
W2065301205
Cited by
45
References
6
FWCI
1.94
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: NILVAD protocol: a European multicentre double-blind placebo-controlled trial of nilvadipine in mild-to-moderate Alzheimer's disease. https://app.cochat.ai/papers/10.1136/bmjopen-2014-006364
The paper
Lawlor, B., Kennelly, S., O'Dwyer, S., Cregg, F., Walsh, C., Coen, R., Kenny, R. A., Howard, R., Murphy, C., Adams, J., Daly, L., Segurado, R., Gaynor, S., Crawford, F., Mullan, M., Lucca, U., Banzi, R., Pasquier, F., Breuilh, L., . . . Olde Rikkert, M. (2014). NILVAD protocol: a European multicentre double-blind placebo-controlled trial of nilvadipine in mild-to-moderate Alzheimer's disease. BMJ Open. https://doi.org/10.1136/bmjopen-2014-006364

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.